Tag Archives: Genmab A/S

Genmab A/S — Friday, December 14th 2018 at 1:58am UTC Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant Submission based on data from Phase …

Genmab A/S — Monday, December 10th 2018 at 6:41pm UTC Company Announcement Copenhagen, Denmark; December 10, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 80,380 restricted stock units to members of the board of directors, management and employees of …

Genmab A/S — Monday, November 26th 2018 at 1:30pm UTC Media Release Event to be held live in San Diego, California Independent experts to discuss data presented at the 2018 ASH Annual Meeting Meeting to be webcast live and archived on www.genmab.com Copenhagen, Denmark; November 26, 2018 – Genmab A/S …

Genmab A/S — Tuesday, November 20th 2018 at 5:20pm UTC Company Announcement Copenhagen, Denmark; November 20, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 7,588 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the …